Pennsylvania Produced DNA COVID-19 Vaccine Candidate Expands Late-Stage Studies
Pennsylvania-based INOVIO announced on October 11, 2021, that it has received authorization from Colombia's Instituto Nacional de Vigilancia de Medicamentos y Alimentos, or the National Food and Drug Surveillance Institute, to conduct the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE, for INO-4800, its DNA vaccine candidate for COVID-19.
INOVIO is working with partner Advaccine Biopharmaceuticals Suzhou Co., Ltd. on the INNOVATE Phase 3 segment in multiple countries, focusing on countries in Latin America, Asia, and Africa.
INOVIO recently announced that it had received regulatory authorization to proceed in Brazil, the Philippines, and Mexico.
And, INOVIO announced the authorization to proceed in China with two Advaccine-sponsored clinical trials investigating the safety, tolerability, and immunogenicity of heterologous boost combinations with INO-4800.
The global Phase 3 segment of INNOVATE will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed COVID-19.
INO-4800 is composed of a precisely designed DNA plasmid injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response.
Dr. J. Joseph Kim, President and CEO of INOVIO, said in a press release, "INOVIO is pleased to share the news of the regulatory authorizations to proceed with our Phase 3 trial."
"With COVID-19 rates continuing to rise in many areas, and with continued limitations to vaccine access in many countries globally, we are grateful to the multiple health authorities who are supporting our efforts to advance the efficacy evaluation of our COVID-19 vaccine."
"INO-4800 is well-positioned to support vaccination efforts in Colombia and beyond, if approved – with the prospects of potentially serving both as a primary series and as a booster vaccine, with a strong thermostability profile and ability to generate neutralizing antibodies and robust T cell responses."
INNOVATE's Phase 3 segment builds upon the Phase 2 segment, which was conducted in the U.S. and funded by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, in coordination with the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency.
Phase 2 data was disclosed in a pre-print in MedRxiv in May 2021 and found INO-4800 to be well-tolerated and immunogenic in adults 18 and older in the trial.
In another previously disclosed study using clinical samples, INO-4800 was also found to provide broad cross-reactive immune responses, including neutralizing antibodies and robust T cell responses, against variants of concern (alpha, beta, gamma and, in subsequent research, delta) – factors which could be critical in containing COVID-19 as it shifts from pandemic to endemic spread.
INOVIO is a biotechnology company located in Plymouth Meeting, PA, committed to powering a new way forward in DNA medicines to save and protect lives worldwide. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from serious and life-threatening diseases associated with HPV, cancer, and infectious diseases.